The sinus dilation devices market is a rapidly growing sector in the global healthcare industry. These devices are used to treat chronic sinusitis by opening up blocked sinus passageways, improving ...
Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Itepekimab is under development for the treatment of chronic ...
The "ENT Handheld Instruments - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.The market is expected to grow at a ...